Please use this identifier to cite or link to this item:
https://doi.org/10.1345/aph.1D153
DC Field | Value | |
---|---|---|
dc.title | Oxaliplatin/Fluorouracil/Leucovorin in Advanced Colorectal Carcinoma: An Asian Experience | |
dc.contributor.author | Lim, E.H. | |
dc.contributor.author | Lim, R.S.C. | |
dc.contributor.author | Wu, T.S. | |
dc.contributor.author | Kong, H.L. | |
dc.date.accessioned | 2016-11-28T10:17:35Z | |
dc.date.available | 2016-11-28T10:17:35Z | |
dc.date.issued | 2003-12 | |
dc.identifier.citation | Lim, E.H., Lim, R.S.C., Wu, T.S., Kong, H.L. (2003-12). Oxaliplatin/Fluorouracil/Leucovorin in Advanced Colorectal Carcinoma: An Asian Experience. Annals of Pharmacotherapy 37 (12) : 1909-1912. ScholarBank@NUS Repository. https://doi.org/10.1345/aph.1D153 | |
dc.identifier.issn | 10600280 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/131217 | |
dc.description.abstract | BACKGROUND: Oxaliplatin/fluorouracil/leucovorin (FOLFOX4) is an effective and generally well-tolerated regimen in Western studies of metastatic colorectal carcinoma. OBJECTIVE: To evaluate the objective tumor responses and toxicities of the FOLFOX4 regimen in a predominantly Chinese population with advanced colorectal carcinoma in Singapore. METHODS: Forty-seven consecutive patients were enrolled in a retrospective study between March 1998 and December 2001. FOLFOX4 was first-line treatment in 36% of these patients, second-line in 36%, third-line in 17%, and fourth-line in 11%. Tumor responses were assessed radiologically, and toxicities were graded by the National Cancer Institute common toxicity system. RESULTS: The objective response rate (all partial responses) was 45%, and stable disease was achieved in 35% of the patients. There were no deaths due to toxicity. Mild to moderate peripheral sensory neuropathy affected half of the patients, with 1 report of cold exacerbation in this tropical series. The rate of hypersensitivity reactions to oxaliplatin was 11%, and they usually occurred late in the treatment course. CONCLUSIONS: FOLFOX4 has good efficacy in metastatic colorectal carcinoma in our local population, but the rate of hypersensitivity reactions to oxaliplatin was high. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1345/aph.1D153 | |
dc.source | Scopus | |
dc.subject | Asian | |
dc.subject | Colorectal carcinoma | |
dc.subject | Hypersensitivity | |
dc.subject | Oxaliplatin | |
dc.type | Article | |
dc.contributor.department | MEDICINE | |
dc.description.doi | 10.1345/aph.1D153 | |
dc.description.sourcetitle | Annals of Pharmacotherapy | |
dc.description.volume | 37 | |
dc.description.issue | 12 | |
dc.description.page | 1909-1912 | |
dc.description.coden | APHRE | |
dc.identifier.isiut | 000186795300027 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.